<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114985</url>
  </required_header>
  <id_info>
    <org_study_id>01-050</org_study_id>
    <nct_id>NCT00114985</nct_id>
  </id_info>
  <brief_title>Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding</brief_title>
  <official_title>A Phase II Study of Late Rectal Toxicity Following 3-D Conformal External Beam Radiation Therapy Performed Using a Prostate Immobilization Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During 3D-conformal external beam radiation therapy treatments for prostate cancer, the
      prostate gland moves. The purpose of this study is to determine whether the placement of a
      prostate immobilization device into the rectum during radiation treatments will decrease the
      risk of rectal bleeding that is sometimes seen as a late effect from radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  MRI using an endorectal coil done prior to treatment for staging.

        -  Baseline Quality of Life (QOL) assessment will be completed prior to treatment.

        -  Total androgen suppression is initiated and will continue for at least 6 months.

        -  Prostate Immobilization Device (PID) placed during the planning session.

        -  PID will be placed daily for the first 15 3D external beam radiation treatments.

        -  QOL assessment and follow-up will take place every 6 months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rectal toxicity at six month intervals</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary symptoms</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sexual dysfunction at six month intervals</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostate Immobilization Device</intervention_name>
    <description>Device placed during radiation treatment</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven prostate cancer

          -  Clinical Stage T1 - T4

          -  Negative bone scan

          -  PSA and routine blood work

          -  &gt;30 years of age

          -  ECOG Performance 0,1, or 2

          -  No prior pelvic radiation

          -  No pacemaker

        Exclusion Criteria:

          -  Inflammatory bowel disease (Crohns, or Ulcerative Colitis)

          -  Prostatic rectal fistula

          -  Stricture of anal canal
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony V. D'Amico, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <reference>
    <citation>Woel R, Beard C, Chen MH, Hurwitz M, Loffredo M, McMahon E, Ching J, Lopes L, D'Amico AV. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):392-6.</citation>
    <PMID>15890580</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2005</study_first_submitted>
  <study_first_submitted_qc>June 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2005</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Anthony V. D'Amico, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Total Androgen Suppression</keyword>
  <keyword>Simulation</keyword>
  <keyword>3-D Conformal External Beam Radiation Therapy</keyword>
  <keyword>Intra-rectal immobilization device</keyword>
  <keyword>Quality of Life Assessment Questionnaire</keyword>
  <keyword>Rectal Bleeding</keyword>
  <keyword>Late effects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

